<DOC>
	<DOCNO>NCT01027845</DOCNO>
	<brief_summary>This study aim evaluate immunogenicity , safety reactogenicity GlaxoSmithKline Biologicals ' 10-valent pneumococcal conjugate vaccine GSK1024850A co-administered Japanese DTPa vaccine 3-dose primary immunization course healthy Japanese child 3 , 4 5 month age booster vaccination 17-19 month age .</brief_summary>
	<brief_title>Primary Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A Healthy Japanese Children</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator/coinvestigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR ( ) ) comply requirement protocol . A male female , include , 90 118 day age ( 3 month ) time first vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . Born gestation period 36 42 week inclusive . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine ( ) , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Planned administration/administration vaccine foreseen study protocol period start 30 day first dose study vaccine ( ) end last study visit , exception Haemophilus influenzae type b vaccine , Hepatitis B Vaccine , Bacille CalmetteGu√©rin vaccine , Oral Polio Vaccine , Japanese encephalitis , measles rubella , varicella , mumps , flu vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Administration pneumococcal vaccine since birth except DTPa group vaccination license pneumococcal vaccine catchup schedule allow 2 vaccine dos administer Study Visit 4 5 , i.e . second blood sample timepoint ( Visit 4 ) onwards 7 day booster dose DTPa vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History , intercurrent diphtheria , tetanus , pertussis disease . History reaction hypersensitivity likely exacerbate component study vaccine . Major congenital defect serious chronic illness . History seizures progressive neurological disease . Administration immunoglobulins and/or blood product since birth plan administration study period . Child care . Acute disease and/or fever time enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>90 Days</minimum_age>
	<maximum_age>118 Days</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pneumococcal disease</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Booster vaccination</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Primary vaccination</keyword>
	<keyword>Safety</keyword>
</DOC>